BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36726287)

  • 1. Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
    Richter J; Lin PL; Garcia-Horton V; Guyot P; Singh E; Zhou ZY; Sievert M; Taiji R
    Cancer Med; 2023 Apr; 12(7):8005-8017. PubMed ID: 36726287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
    Martin TG; Capra M; Mohty M; Suzuki K; Quach H; Cavo M; Moreau P; Dimopoulos M; Yong K; Tekle C; Foster MC; Barnes Y; Risse ML; Mikhael J
    Transplant Cell Ther; 2023 Feb; 29(2):134.e1-134.e7. PubMed ID: 36372355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isatuximab plus carfilzomib and dexamethasone in patients with early
    Facon T; Moreau P; Baker R; Min CK; Leleu X; Mohty M; Karlin L; Armstrong NM; Tekle C; Schwab S; Risse ML; Martin T
    Haematologica; 2024 Feb; 109(2):604-616. PubMed ID: 37584290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.
    Kim K; Min CK; Koh Y; Ishizawa K; Kim SH; Ito S; Tanaka J; Uchiyama M; Kawano Y; Kim JS; Moreau P; Martin T; Dong Y; Risse ML; Suzuki K
    Int J Hematol; 2022 Oct; 116(4):553-562. PubMed ID: 35578151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
    Facon T; Moreau P; Martin TG; Spicka I; Oriol A; Koh Y; Lim A; Mikala G; Rosiñol L; Yağci M; Cavo M; Yong K; Risse ML; Asset G; Schwab S; Martinez G
    Hematol Oncol; 2022 Dec; 40(5):1020-1029. PubMed ID: 35653225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
    Martin T; Mikhael J; Hajek R; Kim K; Suzuki K; Hulin C; Garg M; Quach H; Sia H; George A; Konstantinova T; Risse ML; Asset G; Macé S; van de Velde H; Moreau P
    Blood Adv; 2022 Aug; 6(15):4506-4515. PubMed ID: 35594559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
    Stork M; Spicka I; Radocha J; Minarik J; Jelinek T; Jungova A; Pavlicek P; Pospisilova L; Sedlak F; Straub J; Pika T; Knechtova Z; Fidrichova A; Boichuk I; Sevcikova S; Maisnar V; Hajek R; Pour L
    Ann Hematol; 2023 Jun; 102(6):1501-1511. PubMed ID: 37088816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
    Weisel K; Dimopoulos MA; Beksac M; Leleu X; Richter J; Heeg B; Patel S; Majer I; McFadden I; Mikhael J
    Leuk Lymphoma; 2024 Apr; 65(4):481-492. PubMed ID: 38345269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
    Minarik J; Pika T; Radocha J; Jungova A; Straub J; Jelinek T; Pour L; Pavlicek P; Mistrik M; Brozova L; Krhovska P; Machalkova K; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Capkova L; Sykora M; Kessler P; Stejskal L; Heindorfer A; Ullrychova J; Skacel T; Maisnar V; Hajek R
    BMC Cancer; 2021 Jan; 21(1):73. PubMed ID: 33451293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.
    Banerjee R; Lo M; Martin TG
    Future Oncol; 2021 Dec; 17(35):4849-4860. PubMed ID: 34553603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.
    Kawano Y; Kim K; Min CK; Koh Y; Ishizawa K; Kim SH; Ito S; Tanaka J; Uchiyama M; Ishida T; Kim JS; Moreau P; Martin T; Tada K; Risse ML; Suzuki K
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e360-e367. PubMed ID: 37479547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
    Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Ahmadi T; Qin X; Garvin Mayo W; Gai X; Carey J; Carson R; Moreau P
    J Clin Oncol; 2023 Mar; 41(8):1590-1599. PubMed ID: 36599114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
    Spicka I; Moreau P; Martin TG; Facon T; Martinez G; Oriol A; Koh Y; Lim A; Mikala G; Rosiñol L; Yağci M; Cavo M; Risse ML; Asset G; Macé S; van de Velde H; Yong K
    Eur J Haematol; 2022 Nov; 109(5):504-512. PubMed ID: 35871357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib 56 mg/m
    Weisel K; Nooka AK; Terpos E; Spencer A; Goldschmidt H; Dirnberger F; DeCosta L; Yusuf A; Kumar S
    Leuk Lymphoma; 2022 Aug; 63(8):1887-1896. PubMed ID: 35289710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
    Facon T; Moreau P; Špicka I; Suzuki K; Yong K; Mikhael J; Fukao T; Bisht K; Armstrong NM; Macé S; Risse ML; Martin T
    Hematol Oncol; 2024 Mar; 42(2):e3258. PubMed ID: 38402467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.
    Capra M; Martin T; Moreau P; Baker R; Pour L; Min CK; Leleu X; Mohty M; Segura MR; Turgut M; LeBlanc R; Risse ML; Malinge L; Schwab S; Dimopoulos M
    Haematologica; 2022 Jun; 107(6):1397-1409. PubMed ID: 34647444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
    Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
    Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
    Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
    Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
    Van Sanden S; Ito T; Diels J; Vogel M; Belch A; Oriol A
    Oncologist; 2018 Mar; 23(3):279-287. PubMed ID: 29192016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.